Redeye updates its estimates following Surgical Science’s Q4 2023 report, which featured an unusually soft end to the year that we failed to anticipate. We believe the company’s long-term equity story remains unchanged, though 2023 showed how the market has difficulty pricing the considerable sequential volatility of the company’s sales.

https://www.redeye.se/research/983629/surgical-science-sweden-q4-2023-long-term-high-quality-short-term-black-box?utm_source=finwire&utm_medium=RSS

Redeye